SHANGHAI—Sinocelltech Group Ltd (SHA: 688520), a Chinese biopharmaceutical company, has announced that it has received clearance from the National Medical Products Administration (NMPA) to proceed with a clinical study for its in-house developed anti-angiogenic biologic drug, SCT520FF, for the treatment of neovascular age-related macular degeneration (nAMD).
The drug SCT520FF is a significant addition to the pipeline of treatments targeting nAMD, a leading cause of severe vision loss among the elderly. The approval comes amidst a competitive landscape in China’s ophthalmic market, where established products such as Novartis’s Lucentis (ranibizumab), Bayer’s Eylea (aflibercept), Kanghong Pharma’s Lumitin (conbercept), and Roche’s Vabysmo (faricimab) already hold significant market shares.
Sinocelltech’s SCT520FF is expected to offer a new treatment option for patients suffering from nAMD, potentially improving clinical outcomes and providing an alternative to existing therapies. The company’s commitment to advancing biologic drugs for ocular conditions underscores its role in addressing unmet medical needs in China’s healthcare sector.
The clinical study’s initiation is subject to standard regulatory and ethical approvals, and the results will be crucial in determining the future commercial prospects of SCT520FF. The development of this drug reflects Sinocelltech’s ongoing efforts to innovate in the field of biopharmaceuticals and contribute to the global ophthalmic treatment landscape. – Flcube.com
